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BRIEF TECHNIQUE REPORTSSuccessful combined procedure of HeartMate II left ventricular assist
device implantation and minimally invasive transapical aortic
valve replacementAres K. Menon, MD,a Guido Dohmen, MD,a Andreas H. Mahnken, MD, MBA,b and
R€udiger Autschbach, MD, PhD,a Aachen, GermanyLeft ventricular assist device (LVAD) implantation is an
accepted treatment for patients with end-stage heart fail-
ure, either as a bridge to transplantation or destination
therapy.1,2 The newer continuous-flow LVAD HeartMate
II LVAD (Thoratec Corp, Pleasanton, Calif) represents
the current generation of devices3 and received CE mark
and Food and Drug Administration approval, resulting in
approximately 3500 implantations in patients worldwide.
Severe aortic valve regurgitation remains a strict contra-
diction to the use of LVADs. We present a combined treat-
ment with implantation of a HeartMate II LVAD after
successful transapical aortic valve replacement in a 51-
year-old patient with end-stage heart failure and severe
aortic regurgitation.
Transapical transcatheter aortic valve implantation
(TA-AVI) was introduced to clinical use byWalther and col-
leagues4 in 2007, after the first implantation in humans by
Cribier and colleagues5 in 2002. TA-AVI reflects an alterna-
tive operative strategy to treat aortic valve disease in pa-
tients with advanced age and severe comorbidities, who
present a high risk for open surgery with cardiopulmonary
bypass (CPB).CLINICAL SUMMARY
After failed conservative medical treatment, a 51-year-
old male patient with end-stage heart failure and combined
aortic valve disease with severe regurgitation was admitted
to the intensive care unit. Cardiogenic shock developed in
the patient, and he was treated with inotropes and later
with levosimendan. The patient’s left ventricular ejection
fraction was 15%, and his aortic valve showed severe regur-
gitation and moderate stenosis with an orifice area of 1.2
cm2 and considerable calcification. The cardiac index was
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II antibodies, reflected by a severe decrease in thrombo-
cytes. Therefore, the patient was treated with argatroban in-
stead of heparin.
Because the patient’s left ventricular function did not
recover, an LVAD implantation was planned as a bridge-
to-transplantation procedure. His aortic valve disease com-
bined with severe regurgitation made LVAD implantation
unfeasible. TA-AVI was planned to avoid a conventional
aortic valve replacement. The latter would have caused
additional damage not only to the left ventricle but also to
the already impaired right ventricle.
In the first procedure, a 26-mm Edwards SAPIEN aor-
tic valve (Edwards Lifesciences, Irvine, Calif) was suc-
cessfully implanted under LVAD stand by a transapical
approach through a left-sided anterolateral thoracotomy
under rapid ventricular pacing, as described previously.4
The patient was hemodynamically stable and could be
extubated within 2 hours after surgery. Postoperative
transesophageal echocardiography showed only a mild
paravalvular leak with no relevance. The mean valve gra-
dient was 12 mm Hg.
Despite this promising course, the patient showed no re-
covery tendency in left ventricular function and could not
be weaned from inotropes or levosimendan. Therefore,
the second step was initiated.
LVAD implantation was performed through a median
sternotomy, and CPB was begun under mild hypothermia.
The Thoratec HeartMate II LVAD was implanted at the
apex of the left ventricle under beating heart conditions,
and the pump was positioned in a pre-peritoneal pocket.
The Dacron outflow graft was anastomosed to the ascending
aorta end to side, as recommended by the manufacturers.
Because the patient’s right ventricular function was se-
verely impaired, inhalative nitric oxide was administered
and milrinone was given intravenously, enabling weaning
from CPB and closure of the chest. The preoperative appli-
cation of clopidogrel, argatroban, and aspirin resulted in
bleeding, and surgical reexploration was necessary 18 hours
postoperatively.
Pulmonary function was stabilized after application of
sildenafil, and the patient was successfully weaned from
the ventilator after 4 days. Inotropes were discontinued after
6 days. Phenprocoumon was administered, and after 8 days
the patient was transferred from the intensive care unit to anery c September 2011
FIGURE 1. Overview of the computed tomography scan exhibiting the
transapical aortic valve prosthesis and the LVAD.
Brief Technique Reportsintermediate care unit. Wound healing and mobilization
were uneventful, and the patient was transferred to a rehabil-
itation facility after he was successfully trained in the use of
all equipment.
Transthoracic echocardiography showed good perfor-
mance of both the LVAD and the aortic valve prosthesis,
although a mild paravalvular leakage was observed.
After further successful training in the CoaguCheck
(Roche Diagnostics, Indianapolis, Ind) international
normalized ratio self-testing equipment with a target
area of 2.0 to 2.5, the patient is now receiving out of
hospital care and listed for heart transplantation. Ten
weeks postoperatively, an implantable cardiodefibrilla-
tor was implanted because of reoccurrence of ventricu-
lar arrhythmias.
The actual transesophageal echocardiogram 12 months
after implantation showed a good performance of the
SAPIEN aortic valve and HeartMate II LVAD. The para-
valvular leakage had completely disappeared, but a mild,
central regurgitation jet was observed. The right ventricle
remained impaired, but the size decreased, and the patient
was classified with New York Heart Association class I.The Journal of Thoracic and CaTwelvemonths after discharge, the patient is able to manage
the 6-minute-walk with 500 m.
These clinical findings correlate well with a 64-multislice
computed tomography scan (Figure 1) showing perfect
LVAD position and unimpaired SAPIEN valve position.
To our knowledge, this is the first successful implanta-
tion of a permanent axial LVAD after transapical aortic
valve replacement as a bridge to transplantation. The re-
sults show stable conditions, with no displacement or
thrombosis of the aortic valve prosthesis. Even the mild
paravalvular leak had completely disappeared compared
with the initial findings, with no deterioration under phen-
procoumon and high flow of the LVAD. The excellent clin-
ical recovery of the patient has led to the listing for
orthotopic heart transplant.CONCLUSIONS
In cases of severe aortic valve disease, especially moder-
ate to severe aortic regurgitation, which represents a strict
contraindication for axial LVAD implantation, this com-
bined approach with TA-AVI and LVAD implantation
may be an appropriate solution for select patients with
end-stage heart failure if there is a certain grade of calcifi-
cation to fixate the new valve for a time-consuming, neces-
sary open valve implantation. Further experience is needed
to discern whether this combination therapy will be suc-
cessful after long-term use, particularly in the increasing
number of patients who are not transplantation candidates,
the destination therapy group.References
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